Tarsus Pharmaceuticals, Inc.

TARS · NASDAQ
Analyze with AI
9/30/2025
6/30/2025
3/31/2025
12/31/2024
Operating Activities
Net Income-$13-$20-$25-$23
Dep. & Amort.$0$0$0$0
Deferred Tax$0$0$0$0
Stock-Based Comp.$12$8$7$7
Change in WC$19-$16-$2-$6
Other Non-Cash-$1-$1-$1-$1
Operating Cash Flow$18-$29-$21-$22
Investing Activities
PP&E Inv.-$2-$1-$1-$0
Net Acquisitions$0$0$0$0
Inv. Purchases-$102-$130-$126-$90
Inv. Sales/Matur.$100$79$91$35
Other Inv. Act.$0$0$0-$5
Investing Cash Flow-$5-$52-$35-$60
Financing Activities
Debt Repay.$0$0$0-$32
Stock Issued$3$2$137$3
Stock Repurch.$0$0$0$0
Dividends Paid$0$0$0$0
Other Fin. Act.$0$0$0$32
Financing Cash Flow$3$2$137$3
Forex Effect$0$0$0$0
Net Chg. in Cash$16-$79$81-$79
Supplemental Information
Beg. Cash$99$178$97$176
End Cash$115$99$178$97
Free Cash Flow$16-$30-$21-$27